WHAT IS CLAIMED IS:

1. Use of imeglimin in the manufacture of a medicament for the treatment of type 2 diabetes mellitus wherein an effective amount of imeglimin is to be administered to a human subject in need thereof, wherein the subject has chronic kidney disease.

2. Use of imeglimin in the manufacture of a medicament for the improvement of glycemic control in a subject having type 2 diabetes wherein an effective amount of imeglimin is to be administered to the subject in need thereof, wherein the subject has chronic kidney disease.

3. The use of claim 2, wherein said imeglimin is used as an adjunct to diet and exercise.

4. The use of any one of claims 1 to 3, wherein the subject has mild to severe renal impairment.

5. The use of any one of claims 1 to 4, wherein the subject has moderate renal impairment or stage 3 chronic kidney disease.

6. The use of claim 5, wherein the subject has mild to moderate renal impairment or stage 3A chronic kidney disease.

7. The use of claim 5, wherein the subject has moderate to severe renal impairment or stage 3B chronic kidney disease.

8. The use of any one of claims 1 to 4, wherein the subject has severe renal impairment or stage 4 chronic kidney disease.

9. The use of any one of claims 1 to 4, wherein the subject has stage 3B or stage 4 chronic kidney disease.

10. The use of any one of claims 1 to 9, wherein the subject has an estimated glomerular filtration rate (eGFR) of between 30 ml/min/1.73m^2 and 59 ml/min/1.73m^2.

11. The use of claim 10, wherein the subject has an eGFR of between 45ml/min/1.73m^2 and 59 ml/min/1.73m^2.

12. The use of claim 10, wherein the subject has an eGFR of between 30 ml/min/1.73m^2 and 44 ml/min/1.73m^2.

13. The use of any one of claims 1 to 9, wherein the subject has an estimated glomerular filtration rate (eGFR) of between 15 ml/min/1.73m^2 and 29 ml/min/1.73m^2.

14. The use of any one of claims 1 to 9, wherein the subject has an estimated glomerular filtration rate (eGFR) of between 15 ml/min/1.73m^2 and 44 ml/min/1.73m^2.

15. The use of any one of claims 1 to 14, wherein the subject has a baseline glycosylated hemoglobin (HbA1c) percentage of between 6.8% and 12.0%.

16. The use of any one of claims 1 to 15, wherein the subject has a further pre-existing medical condition.

17. The use of claim 16, wherein the further pre-existing medical condition is selected from hyperkalaemia, hypertension, cardiac disorders, gastrointestinal disorders, nervous system disorders, blood and lymphatic system disorders (such as anemia), eye disorders, endocrine disorders, or combinations thereof.

18. The use of any one of claims 1 to 15, wherein the imeglimin-treated subject has a similar or the same frequency of treatment-emergent adverse events as a placebo-treated subject.

19. The use of claim 16 or 17, wherein the imeglimin-treated subject does not experience an increase in one or more symptoms of the subject's one or more pre-existing medical conditions compared to before the subject initiated imeglimin treatment.

20. The use of claim 16 or 17, wherein the imeglimin-treated subject's one or more pre-existing conditions do not worsen in severity or symptomatology following treatment with imeglimin.

21. The use of claim 20, wherein the imeglimin-treated subject's one or more pre-existing conditions do not worsen in severity or symptomatology following treatment with imeglimin compared to before the subject initiated imeglimin treatment.

22. The use of claim 20, wherein the imeglimin-treated subject's one or more pre-existing conditions do not worsen in severity or symptomatology following treatment with imeglimin compared to that which would be expected if the subject took a second pharmaceutical agent.

23. The use of claim 17, wherein the pre-existing medical condition is a gastrointestinal disorder.

24. The use of claim 23, wherein the gastrointestinal disorder is selected from abdominal pain, constipation, diarrhea, flatulence, gastroesophageal reflux, indigestion, nausea/vomiting, or combinations thereof.

25. The use of any one of claims 1 to 24, wherein imeglimin is well tolerated.

26. The use of any one of claims 1 to 25, wherein the imeglimin-treated subject does not experience an increase in frequency of lactic acidosis compared to before the subject initiated imeglimin treatment.

27. The use of any one of claims 1 to 26, wherein the imeglimin-treated subject does not experience an increase or elevation in plasma lactate compared to before the subject initiated imeglimin treatment.

28. The use of claim 27, wherein the imeglimin-treated subject does not experience an increase or elevation in plasma lactate above a threshold of 3 mmol/L (27 mg/dL) compared to before the subject initiated imeglimin treatment.

29. The use of any one of claims 1 to 28, wherein the imeglimin-treated subject is no more likely or is less likely than a placebo-treated subject or subject treated with a second pharmaceutical agent to experience an increase or elevation in plasma lactate compared to before the subject initiated imeglimin treatment.

30. The use of any one of claims 1 to 29, wherein imeglimin is to be administered orally.

31. The use of any one of claims 1 to 30, wherein the amount of imeglimin to be administered to the subject per day is 20% to 100% of the amount to be administered to a subject with type 2 diabetes mellitus but with normal kidney function.

32. The use of any one of claims 1 to 31, wherein the amount of imeglimin is 500 mg to 3000 mg per day.

33. The use of claim 32, wherein the amount of imeglimin is 1000 mg to 3000 mg per day.

34. The use of claim 33, wherein the amount of imeglimin is 1000 mg to 2000 mg per day.

35. The use of any one of claims 1 to 34, wherein the amount of imeglimin is 1000 mg, 1500 mg, or 2000 mg per day.

36. The use of any one of claims 1 to 33, wherein imeglimin is to be administered once, twice, or three times per day.

37. The use of claim 36, wherein imeglimin is to be administered twice per day.

38. The use of claim 36, wherein imeglimin is to be administered 500 mg twice a day, 1000 mg twice a day, or 1500 mg once a day.

39. The use of any one of claims 1 to 38, wherein imeglimin is to be administered with a meal.

40. The use of any one of claims 1 to 38, wherein imeglimin is to be administered without a meal.

41. The useof any one of claims 1 to 40, wherein imeglimin is to be administered in the form of a free base or a pharmaceutically acceptable salt thereof.

42. The use of claim 41, wherein imeglimin is to be administered in the form a hydrochloride salt.

43. The use of any one of claims 1 to 42, wherein the subject experiences a placebo-subtracted decrease in glycosylated hemoglobin (HbA1c) percentage of between -0.5% and -1.2% over a treatment period.

44. The use of claim 43, wherein the subject experiences a placebo-subtracted decrease in glycosylated hemoglobin (HbA1c) percentage of between -0.8% and -1.1% over a treatment period.

45. The use of any one of claims 1 to 44, wherein the subject experiences a placebo-subtracted decrease in fasting plasma glucose (FPG) of between -20 mg/dL and -30 mg/dL over a treatment period.

46. The use of claim 45, wherein the subject experiences a placebo-subtracted decrease in fasting plasma glucose (FPG) of -25 mg/dL over a treatment period.

47. The use of any one of claims 43 to 46, wherein the treatment period is from 4 weeks to 52 weeks.

48. The use of claim 47, wherein the treatment period is 24 weeks.

49. The use of any one of claims 1 to 48, wherein the subject has daily steady-state exposures of imeglimin ($AUC_{24,ss}$) from 20 µg·hr/mL to 100 µg·hr/mL.

50. The use of any one of claims 1 to 49, wherein the subject has received prior anti-diabetic treatment.

51. The use of claim 50, wherein the prior anti-diabetic treatment does not provide adequate control of or does not adequately control the subject's type 2 diabetes mellitus.

52. The use of any one of claims 1 to 49, wherein the subject has not received prior anti-diabetic treatment.

53. The use of any one of claims 1 to 52, wherein imeglimin is to be administered with a second pharmaceutical agent.

54. The use of claim 53, wherein imeglimin is to be administered concomitantly with the second pharmaceutical agent.

55. The use of claim 53, wherein imeglimin is to be administered sequentially with the second pharmaceutical agent.

56. The use of any one of claims 53 to 55, wherein the second pharmaceutical agent is selected from the group consisting of an insulin, an alpha-glucosidase inhibitor, a biguanide, a dopamine agonist, a DPP-4 inhibitor, a glucagon-like peptide, a meglitinide, a sodium glucose transporter (SGLT2 or SGLT1/2) inhibitor, a sulfonylurea, and a thiazolidinedione.

57. The use of any one of claims 53 to 56, wherein the second pharmaceutical agent is metformin.

58. The use of any one of claims 53 to 56, wherein the second pharmaceutical agent is sitagliptin.

.